Skip to main content

Sara Isabel Reidel

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Sara Isabel Reidel

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

Integración de datos del mundo real, de salud y de investigación para la mejora de los protocolos clínicos en la enfermedad falciforme y otras anemias raras

IP: M Mar Mañu Pereira
Collaborators: Sara Isabel Reidel, David Beneitez Pastor, Maria Cristina Díaz de Heredia Rubio, Adoración Blanco Alvarez
Funding agency: Instituto de Salud Carlos III
Funding: 152500
Reference: PI24/00477
Duration: 01/01/2025 - 31/12/2027

ERDERA: European Rare Disease Research Alliance

IP: M Mar Mañu Pereira
Collaborators: Augusto Cesar Sao Aviles, Patricia González Ruiz, Claire Diot, Miguel Chillon Rodriguez, Simon Schwartz Navarro, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 1252083.33
Reference: ERDERA/EC/HLTH-2023-DISEASE-07-01/2023/MAÑU
Duration: 01/09/2024 - 31/08/2031

ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases)

IP: M Mar Mañu Pereira
Collaborators: Raquel Mosull del Campo, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 1569581.5
Reference: EUROBLOODNET-ERN_EU4H2023
Duration: 01/10/2023 - 30/09/2027

ERN-EuroBloodNet: EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES

IP: M Mar Mañu Pereira
Collaborators: Reidel , Sara Isabel, Claire Diot, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 371825
Reference: EUROBLOODNETBR2022_EU4H-ERN2022
Duration: 01/05/2022 - 30/11/2023

Related news

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The charitable initiative will allocate all funds to research on pediatric nervous system tumors carried out at the Vall d’Hebron Research Institute

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

Related professionals

Ana Rosa Olmo Muñoz

Ana Rosa Olmo Muñoz

Neurovascular Diseases
Read more
Mamadou Fall Sarr

Mamadou Fall Sarr

Research assistant
Infectious Diseases
Read more
Luciano Rodríguez Gómez

Luciano Rodríguez Gómez

Senior researcher
Transfusional Medicine
Read more
Maximo Tartaglia

Maximo Tartaglia

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.